PNR-4-20 Showed Less Tolerance for Some Mouse Effects, Not a Universal Advantage
An experimental cannabinoid agonist produced less tolerance than THC or JWH-018 for selected mouse outcomes. The finding was specific to the effects measured and does not establish that the compound is generally safer or clinically superior.
Comparing different CB1 agonists
The study examined PNR-4-20, described as a G protein-biased agonist, alongside THC and JWH-018 in male mice. Repeated administration was followed by tests of temperature, antinociception and catalepsy, with additional observations after abstinence.
Some responses showed less adaptation
The abstract reports less tolerance to PNR-4-20's hypothermic and cataleptic effects. It also describes recovery after abstinence, asymmetric cross-tolerance with THC for hypothermia and less CB1 receptor downregulation in specified brain regions relative to THC.
Signaling bias is not a clinical outcome
A tendency to favor one signaling pathway describes pharmacology under particular assay conditions. It does not directly establish freedom from intoxication, dependence or adverse effects. Nor does a lower tolerance effect on body temperature guarantee retained analgesia under other regimens.
The compounds were administered at different amounts intended for comparison within this experiment. Their milligram doses should not be treated as equivalent consumer exposures. These data identify a research lead rather than a substitute for cannabis or a human prescribing strategy. Any account of the result should retain the species, comparison drug, endpoint and repeated-treatment schedule.
Related: interpreting cannabis tolerance claims.
Research cited
Ford BM; Cabanlong CV; Tai S; Franks LN; Penthala NR; Crooks PA; Prather PL; Fantegrossi WE. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018. The Journal of pharmacology and experimental therapeutics (2019). doi:10.1124/jpet.118.252965. Findings discussed from the study abstract.
